ReviewFrontiers in neurology
Serum neurofilament light chain in multiple sclerosis: from biological signal to clinically informed decision-making.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum neurofilament light chain (sNfL) is an analytically robust blood-based biomarker of recent neuroaxonal injury in multiple sclerosis (MS), supported by validated ultrasensitive immunoassays suitable for routine measurement. These assays now enable reliable measurement in routine care, and evidence links higher levels and rising trajectories to inflammatory activity, treatment response, and-at a population level-future tissue loss and disability risk. Clinical implementation is constrained by overinterpretation of single measurements: sNfL is not MS-specific, is strongly age-dependent, is influenced by systemic and neurological confounders, and reflects injury over weeks to months rather than cumulative neurodegeneration. This review proposes a clinically oriented framework in which sNfL serves as decision support alongside MRI and clinical assessment, not as a stand-alone trigger for therapy changes. We prioritize longitudinal interpretation anchored to an individual baseline or nadir, the use of age-adjusted reference frameworks (percentiles or Z-scores where available), standardization of key pre-analytical and analytical conditions, and structured approaches to discordance between biomarkers, imaging, and symptoms. We discuss the complementary role of serum glial fibrillary acidic protein (sGFAP) as a marker of chronic astroglial pathology and progression-dominant biology, and how combined biomarker patterns may refine interpretation when disability worsens despite limited inflammatory activity. Across the MS continuum-from prodromal states and radiologically isolated syndrome to relapsing and progressive phenotypes-we summarize practical use cases, limitations, and safety-critical "red flags" where marked sNfL surges warrant urgent reassessment. Finally, we highlight consensus-based implementation principles and research priorities, including pragmatic trials to test whether biomarker-informed strategies improve patient-relevant outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.